Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

× No keyword cloud information.

13 in total

1. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

Authors: Howard L McLeod; Daniel J Sargent; Sharon Marsh; Erin M Green; Cristi R King; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Stephen N Thibodeau; Axel Grothey; Roscoe F Morton; Richard M Goldberg
Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544

2. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors: Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal: Int J Clin Oncol Date: 2011-10-15 Impact factor: 3.402

3. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.

Authors: Justin Guinney; Charles Ferté; Jonathan Dry; Robert McEwen; Gilles Manceau; K J Kao; Kai-Ming Chang; Claus Bendtsen; Kevin Hudson; Erich Huang; Brian Dougherty; Michel Ducreux; Jean-Charles Soria; Stephen Friend; Jonathan Derry; Pierre Laurent-Puig
Journal: Clin Cancer Res Date: 2013-10-29 Impact factor: 12.531

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

1. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

2. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

3. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.

Review 4. Implementing prognostic and predictive biomarkers in CRC clinical trials.

5. Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer.

Review 6. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.

Review 7. [Molecular targets for colon cancer. VEGF, EGFR - and what else?].

8. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

9. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models.

Review 10. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.